Key facts
- 52-week range (closes)
- $69.10 – $147.53 Lowest close Oct 1, 2026, highest Oct 27, 2025; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- December Fiscal 2025 ended Dec 31, 2025, from SEC filings
- In the S&P 500 since
- Jun 21, 2013 · All S&P 500 changes
Zoetis (ZTS) is trading down at $79.58 (-0.01%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Zoetis revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $4.89B | $5.31B | $5.83B | $6.26B | $6.67B | $7.78B | $8.08B | $8.54B | $9.26B | $9.47B |
| Growth (year over year) | +2.6% | +8.6% | +9.8% | +7.5% | +6.6% | +16.5% | +3.9% | +5.7% | +8.3% | +2.3% |
| Gross profit | $3.22B | $3.53B | $3.91B | $4.27B | $4.62B | $5.47B | $5.63B | $5.98B | $6.54B | $6.80B |
| Gross margin | 65.9% | 66.6% | 67.2% | 68.2% | 69.2% | 70.4% | 69.6% | 70.0% | 70.6% | 71.8% |
| Net income | $821.0M | $864.0M | $1.43B | $1.50B | $1.64B | $2.04B | $2.11B | $2.34B | $2.49B | $2.67B |
| Net margin | 16.8% | 16.3% | 24.5% | 24.0% | 24.5% | 26.2% | 26.2% | 27.4% | 26.9% | 28.2% |
| EPS (diluted) | $1.65 | $1.75 | $2.93 | $3.11 | $3.42 | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 |
| Balance sheet | ||||||||||
| Cash and equivalents | $727.0M | $1.56B | $1.60B | $1.93B | $3.60B | $3.48B | $3.58B | $2.04B | $1.99B | $2.45B |
| Total assets | $7.65B | $8.59B | $10.8B | $11.5B | $13.6B | $13.9B | $14.9B | $14.3B | $14.2B | $15.5B |
| Total liabilities | $6.15B | $6.80B | $8.59B | $8.84B | $9.84B | $9.36B | $10.5B | $9.29B | $9.47B | $12.1B |
| Long-term debt | $4.47B | $4.95B | $6.44B | $5.95B | $6.59B | $6.59B | $6.55B | $6.56B | $5.22B | $9.04B |
| Shareholders' equity | $1.49B | $1.77B | $2.19B | $2.71B | $3.77B | $4.54B | $4.41B | $5.00B | $4.77B | $3.42B |
| Cash flow | ||||||||||
| Operating cash flow | $713.0M | $1.35B | $1.79B | $1.79B | $2.13B | $2.21B | $1.91B | $2.35B | $2.95B | $2.90B |
| Capital expenditure | $216.0M | $224.0M | $338.0M | $460.0M | $453.0M | $477.0M | $586.0M | $732.0M | $655.0M | $621.0M |
| Free cash flow | $497.0M | $1.12B | $1.45B | $1.33B | $1.67B | $1.74B | $1.33B | $1.62B | $2.30B | $2.28B |
| Share buybacks | $300.0M | $500.0M | $698.0M | $626.0M | $250.0M | $743.0M | $1.59B | $1.09B | $1.86B | $3.23B |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.39B | $2.32B | $2.20B | $2.47B | $2.40B | $2.40B | $2.26B | $2.47B |
| Growth (year over year) | +11.0% | +4.7% | +0.4% | +4.8% | +0.5% | +3.4% | +2.9% | −0.2% |
| Gross profit | $1.69B | $1.61B | $1.58B | $1.81B | $1.72B | $1.69B | $1.62B | $1.79B |
| Gross margin | 70.6% | 69.5% | 71.9% | 73.2% | 71.5% | 70.7% | 71.7% | 72.7% |
| Net income | $682.0M | $581.0M | $602.0M | $726.0M | $721.0M | $624.0M | $601.0M | $691.0M |
| Net margin | 28.6% | 25.1% | 27.4% | 29.3% | 30.0% | 26.1% | 26.6% | 28.0% |
| EPS (diluted) | $1.50 | $1.29 | $1.34 | $1.63 | $1.63 | $1.42 | $1.42 | $1.65 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.71B | $1.99B | $1.72B | $1.44B | $2.08B | $2.45B | $1.94B | $1.48B |
| Total assets | $14.4B | $14.2B | $14.1B | $14.5B | $15.2B | $15.5B | $15.2B | $15.1B |
| Total liabilities | $9.12B | $9.47B | $9.44B | $9.50B | $9.76B | $12.1B | $11.9B | $11.9B |
| Long-term debt | $6.57B | $5.22B | $5.23B | $5.23B | $7.07B | $9.04B | $9.04B | $9.05B |
| Shareholders' equity | $5.23B | $4.77B | $4.66B | $4.98B | $5.40B | $3.42B | $3.23B | $3.15B |
| Cash flow | ||||||||
| Operating cash flow | $951.0M | $905.0M | $515.0M | $605.0M | $891.0M | $893.0M | $401.0M | $655.0M |
| Capital expenditure | $167.0M | $216.0M | $178.0M | $146.0M | $136.0M | $161.0M | $110.0M | $117.0M |
| Free cash flow | $784.0M | $689.0M | $337.0M | $459.0M | $755.0M | $732.0M | $291.0M | $538.0M |
| Share buybacks | $433.0M | $553.0M | $443.0M | $338.0M | $394.0M | $2.06B | $606.0M | $584.0M |
From Zoetis's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Zoetis vs the Health Care sector and the S&P 500
Zoetis's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | Zoetis | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | +2.3% | +7.2% | +7.0% |
| Net margin, latest fiscal year | 28.2% | 12.9% | 12.9% |
| Dividend per share, latest fiscal year | $2.03 | $2.48 | $2.40 |
| Share price change, 1 year | −45.1% | +19.8% | +5.9% |
Zoetis: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Zoetis included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.
About Zoetis
Zoetis Inc. (/zō-EH-tis/), headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries.
- Headquarters
- Parsippany, New Jersey From SEC filings, Oct 2026
Recent News (20)
-
Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers StockStory
-
Zoetis at Morgan Stanley conference: pipeline offsets near-term pressure
Zoetis at Morgan Stanley conference: pipeline offsets near-term pressure
-
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
-
-
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? Trefis
-
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For? Trefis
-
Zoetis (ZTS) Shares Drop After Earnings Revision
Zoetis (ZTS) Shares Drop After Earnings Revision
-
Is Zoetis Stock Underperforming the S&P 500?
Is Zoetis Stock Underperforming the S&P 500?
-
TD Cowen cuts Zoetis stock price target on clinic visit declines TD Cowen cuts Zoetis stock price target on clinic visit declines Investing.com
-
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
-
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
-
Zoetis (ZTS) Remains a Leader, So Why Was It Sold?
Zoetis (ZTS) Remains a Leader, So Why Was It Sold?
-
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
-
BNP Paribas Exane Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price BNP Paribas Exane Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price MarketBeat
-
Zoetis Stock: Is Wall Street Bullish or Bearish? Zoetis Stock: Is Wall Street Bullish or Bearish?
-
Zoetis (ZTS) Looked Like a Winner. What Went Wrong? Zoetis (ZTS) Looked Like a Winner. What Went Wrong?
-
Zoetis Q2 Earnings Call Highlights Zoetis Q2 Earnings Call Highlights
-
Zoetis Inc. Q2 2026 Earnings Call Summary Zoetis Inc. Q2 2026 Earnings Call Summary
-
Zoetis stock falls on weak guidance despite earnings beat
Zoetis stock falls on weak guidance despite earnings beat
-
More Health Care stocks
- VTRS Viatris
- WAT Waters Corporation
- WST West Pharmaceutical Services
- ZBH Zimmer Biomet
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology